Lactoferrin/pectin nanocomplex encapsulating ciprofloxacin and naringin as a lung targeting antibacterial

Shaymaa A Mohamed1, Hoda E Mahmoud1, Amira M Embaby1

  • 1Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria 21526, Egypt.

Insights

This study developed a novel nanoplatform encapsulating ciprofloxacin and naringin to combat Pseudomonas aeruginosa infections. The formulation effectively reduced bacterial load and oxidative stress, showing promise for enhanced antibiotic therapy.

Area of Science:

  • Nanotechnology
  • Antimicrobial drug delivery
  • Bacterial infection research

Background:

  • Pseudomonas aeruginosa is an opportunistic pathogen causing severe hospital-acquired infections.
  • Antibiotic resistance and oxidative stress complicate treatment of P. aeruginosa infections.
  • Reactive oxygen species (ROS) are implicated in infection and antibiotic-induced toxicity.

Purpose of the Study:

  • To develop a polyelectrolyte complex (PEX) for co-encapsulating ciprofloxacin (CPR) and naringin (NAR).
  • To evaluate the PEX's ability to enhance CPR's antibacterial efficacy and mitigate oxidative stress.
  • To assess the PEX's suitability for targeted lung delivery and in vivo therapeutic potential.

Main Methods:

  • Fabrication of a lactoferrin (LF)/pectin (PEC) polyelectrolyte complex (PEX) loaded with CPR and NAR.
  • Characterization of PEX particle size, zeta potential, and encapsulation efficiency (EE%).
  • In vitro release studies, hemocompatibility, and in vivo efficacy assessment in infected mice (CFU counts, oxidative stress markers).

Main Results:

  • CPR/NAR-loaded PEX exhibited optimal physicochemical properties (237 nm size, -23 mV zeta potential, high EE%).
  • Sequential release of CPR and NAR from PEX demonstrated sustained antibacterial activity and ROS mitigation.
  • In vivo studies showed significant reduction in bacterial load, oxidative stress (increased GSH/CAT, decreased MDA), and improved organ function in treated mice.

Conclusions:

  • CPR/NAR-loaded PEX represents a promising nanoplatform for targeted lung delivery.
  • The PEX enhances ciprofloxacin efficacy against P. aeruginosa while reducing associated oxidative stress.
  • This approach offers a potential strategy for improved management of challenging bacterial infections.